Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 1939-1948

  Mo, Xiu Lei ^a   Tao, Ya Xiong ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Biased signaling; Constitutive activity; Inverse agonist; Melanocortin 4 receptor

Indexed keywords

MELANOCORTIN 4 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 84882740707     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.06.006     Document Type: Article

References (59)

1. Tao Y.X., Yuan Z.H., Xie J. G protein-coupled receptors as regulators of energy homeostasis. Prog. Mol. Biol. Transl. Sci. 2013, 114:1-43.
2. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
3. Balthasar N., Dalgaard L.T., Lee C.E., Yu J., Funahashi H., Williams T., Ferreira M., Tang V., McGovern R.A., Kenny C.D., Christiansen L.M., Edelstein E., Choi B., Boss O., Aschkenasi C., Zhang C.Y., Mountjoy K., Kishi T., Elmquist J.K., Lowell B.B. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 2005, 123:493-505.
4. Farooqi I.S., Keogh J.M., Yeo G.S., Lank E.J., Cheetham T., O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 2003, 348:1085-1095.
5. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol. Cell. Endocrinol. 2005, 239:1-14.
6. Tao Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev. 2010, 31:506-543.
7. Hinney A., Volckmar A.L., Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog. Mol. Biol. Transl. Sci. 2013, 114:147-191.
8. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., DelValle J., Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem. 1993, 268:15174-15179.
9. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165-168.
10. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., Barsh G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278:135-138.
11. Tao Y.X. Mutations in melanocortin-4 receptor and human obesity. Prog. Mol. Biol. Transl. Sci. 2009, 88:173-204.
12. Tao Y.X., Segaloff D.L. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 2003, 144:4544-4551.
13. Tao Y.X., Segaloff D.L. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J. Clin. Endocrinol. Metab. 2005, 90:5632-5638.
14. Fan Z.C., Tao Y.X. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J. Cell. Mol. Med. 2009, 13:3268-3282.
15. Wang Z.Q., Tao Y.X. Functional studies on twenty novel naturally occurring melanocortin-4 receptor mutations. Biochim. Biophys. Acta 2011, 1812:1190-1199.
16. Vaisse C., Clement K., Durand E., Hercberg S., Guy-Grand B., Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 2000, 106:253-262.
17. Tao Y.X. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanism of activation and therapeutics. Pharmacol. Ther. 2008, 120:129-148.
18. Stutzmann F., Tan K., Vatin V., Dina C., Jouret B., Tichet J., Balkau B., Potoczna N., Horber F., O'Rahilly S., Farooqi I.S., Froguel P., Meyre D. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 2008, 57:2511-2518.
19. Hinney A., Hohmann S., Geller F., Vogel C., Hess C., Wermter A.K., Brokamp B., Goldschmidt H., Siegfried W., Remschmidt H., Schafer H., Gudermann T., Hebebrand J. Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J. Clin. Endocrinol. Metab. 2003, 88:4258-4267.
20. Proneth B., Xiang Z., Pogozheva I.D., Litherland S.A., Gorbatyuk O.S., Shaw A.M., Millard W.J., Mosberg H.I., Haskell-Luevano C. Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism. Chem. Biol. Drug Des. 2006, 67:215-229.
21. Tao Y.X., Huang H., Wang Z.Q., Yang F., Williams J.N., Nikiforovich G.V. Constitutive activity of neural melanocortin receptors. Methods Enzymol. 2010, 484:267-279.
22. Beckers S., Zegers D., de Freitas F., Peeters A.V., Verhulst S.L., Massa G., Van Gaal L.F., Timmermans J.P., Desager K.N., Van Hul W. Identification and functional characterization of novel mutations in the melanocortin-4 receptor. Obes. Facts 2010, 3:304-311.
23. Daniels D., Patten C.S., Roth J.D., Yee D.K., Fluharty S.J. Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus. Brain Res. 2003, 986:1-11.
24. Vongs A., Lynn N.M., Rosenblum C.I. Activation of MAP kinase by MC4-R through PI3 kinase. Regul. Pept. 2004, 120:113-118.
25. Chai B., Li J.Y., Zhang W., Newman E., Ammori J., Mulholland M.W. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides 2006, 27:2846-2857.
26. Sutton G.M., Duos B., Patterson L.M., Berthoud H.R. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005, 146:3739-3747.
27. Patten C.S., Daniels D., Suzuki A., Fluharty S.J., Yee D.K. Structural and signaling requirements of the human melanocortin 4 receptor for MAP kinase activation. Regul. Pept. 2007, 142:111-122.
28. Mo X.L., Yang R., Tao Y.X. Functions of transmembrane domain 3 of human melanocortin-4 receptor. J. Mol. Endocrinol. 2012, 49:221-235.
29. Huang H., Tao Y.X. Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor. J. Mol. Endocrinol. 2012, 49:237-248.
30. Chaki S., Ogawa S., Toda Y., Funakoshi T., Okuyama S. Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents. Eur. J. Pharmacol. 2003, 474:95-101.
31. Poitout L., Brault V., Sackur C., Bernetiere S., Camara J., Plas P., Roubert P. Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 2007, 17:4464-4470.
32. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., Drabic S.V., Horlick R.A., Lamppu D., Yowe D.L., Balani S., Li P., Zeng H., Joseph I.B., Rodriguez L.E., Maguire M.P., Patane M.A., Claiborne C.F. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J. Med. Chem. 2004, 47:1602-1604.
33. Mellon P.L., Windle J.J., Goldsmith P.C., Padula C.A., Roberts J.L., Weiner R.I. Immortalization of hypothalamic GnRH neurons by genetically targeted tumorigenesis. Neuron 1990, 5:1-10.
34. Fan Z.C., Sartin J.L., Tao Y.X. Molecular cloning and pharmacological characterization of porcine melanocortin-3 receptor. J. Endocrinol. 2008, 196:139-148.
35. Damm E., Buech T.R., Gudermann T., Breit A. Melanocortin-induced PKA activation inhibits AMPK activity via ERK-1/2 and LKB-1 in hypothalamic GT1-7 cells. Mol. Endocrinol. 2012, 26:643-654.
36. Khong K., Kurtz S.E., Sykes R.L., Cone R.D. Expression of functional melanocortin-4 receptor in the hypothalamic GT1-1 cell line. Neuroendocrinology 2001, 74:193-201.
37. Nijenhuis W.A., Oosterom J., Adan R.A. AgRP(83-132) acts as an inverse agonist on the human melanocortin-4 receptor. Mol. Endocrinol. 2001, 15:164-171.
38. Chai B.X., Neubig R.R., Millhauser G.L., Thompson D.A., Jackson P.J., Barsh G.S., Dickinson C.J., Li J.Y., Lai Y.M., Gantz I. Inverse agonist activity of agouti and agouti-related protein. Peptides 2003, 24:603-609.
39. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., Hofbauer K.G. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J. Pharmacol. Exp. Ther. 2006, 317:771-777.
40. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
41. Haskell-Luevano C., Monck E.K. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul. Pept. 2001, 99:1-7.
42. Tolle V., Low M.J. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes 2008, 57:86-94.
43. Wu Q., Howell M.P., Cowley M.A., Palmiter R.D. Starvation after AgRP neuron ablation is independent of melanocortin signaling. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2687-2692.
44. Breit A., Buch T.R., Boekhoff I., Solinski H.J., Damm E., Gudermann T. Alternative G protein coupling and biased agonism: new insights into melanocortin-4 receptor signalling. Mol. Cell. Endocrinol. 2011, 331:232-240.
45. Buch T.R., Heling D., Damm E., Gudermann T., Breit A. Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist. J. Biol. Chem. 2009, 284:26411-26420.
46. Pace A.M., Faure M., Bourne H.R. Gi2-mediated activation of the MAP kinase cascade. Mol. Biol. Cell 1995, 6:1685-1695.
47. Ferraguti F., Baldani-Guerra B., Corsi M., Nakanishi S., Corti C. Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur. J. Neurosci. 1999, 11:2073-2082.
48. Breit A., Wolff K., Kalwa H., Jarry H., Buch T., Gudermann T. The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors. J. Biol. Chem. 2006, 281:37447-37456.
49. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T., Bouvier M., Pineyro G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11406-11411.
50. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy S.K., Lefkowitz R.J. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16657-16662.
51. Wei H., Ahn S., Shenoy S.K., Karnik S.S., Hunyady L., Luttrell L.M., Lefkowitz R.J. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10782-10787.
52. Shenoy S.K., Drake M.T., Nelson C.D., Houtz D.A., Xiao K., Madabushi S., Reiter E., Premont R.T., Lichtarge O., Lefkowitz R.J. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 2006, 281:1261-1273.
53. Zhai P., Yamamoto M., Galeotti J., Liu J., Masurekar M., Thaisz J., Irie K., Holle E., Yu X., Kupershmidt S., Roden D.M., Wagner T., Yatani A., Vatner D.E., Vatner S.F., Sadoshima J. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J. Clin. Invest. 2005, 115:3045-3056.
54. Warne T., Edwards P.C., Leslie A.G., Tate C.G. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 2012, 20:841-849.
55. Wacker D., Wang C., Katritch V., Han G.W., Huang X.P., Vardy E., McCorvy J.D., Jiang Y., Chu M., Siu F.Y., Liu W., Xu H.E., Cherezov V., Roth B.L., Stevens R.C. Structural features for functional selectivity at serotonin receptors. Science 2013, 340:615-619.
56. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2002, 366:381-416.
57. Srinivasan S., Lubrano-Berthelier C., Govaerts C., Picard F., Santiago P., Conklin B.R., Vaisse C. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 2004, 114:1158-1164.
58. Grill H.J., Ginsberg A.B., Seeley R.J., Kaplan J.M. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J. Neurosci. 1998, 18:10128-10135.
59. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.